Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Fineline Cube Jul 29, 2026
Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Fineline Cube Jul 29, 2026
Company Deals

Medilink Therapeutics Collaborates with Wuhan Union Hospital on Clinical Trials

Fineline Cube May 26, 2025

Suzhou-based Medilink Therapeutics announced a clinical study collaboration agreement with Union Hospital, Tongji Medical College,...

Company Drug

Duality Biologics Receives FDA IND Approval for EGFR/HER3 ADC AVZO-1418

Fineline Cube May 26, 2025

Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United...

Company Drug

Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial

Fineline Cube May 26, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from...

Company Drug

Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals

Fineline Cube May 26, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency’s (EMA) Committee for...

Company Deals

Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody

Fineline Cube May 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...

Company Drug

Roche’s Itovebi Recommended for EU Approval in PIK3CA-Mutated Breast Cancer

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its Itovebi (inavolisib) has been...

Company Medical Device

Jenscare Announces Positive 30-Day Results for LuX-Valve Plus in TRINITY Study

Fineline Cube May 26, 2025

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company Deals

Roche Partners with Broad Clinical Labs to Advance SBX Sequencing Technology

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced last week a strategic partnership with...

Company Drug

Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis

Fineline Cube May 26, 2025

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...

Company Medical Device

Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications

Fineline Cube May 26, 2025

US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA)...

Company Deals

Tonghua Dongbao to Sell Stake in Amoytop Biotech for USD 181 Million

Fineline Cube May 24, 2025

Chinese pharmaceutical firm Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) has announced plans to divest...

Company Deals

Shandong Boan Biotechnology Partners with HKUST for Biomedicine Innovation

Fineline Cube May 24, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has entered into a partnership with the...

Company Deals

PacBio Appoints Haorui Gene as Official Distributor in China

Fineline Cube May 24, 2025

US-based sequencing solutions provider PacBio (NASDAQ: PACB) has appointed China’s Haorui Gene as an official...

Company Drug

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

Fineline Cube May 23, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...

Company Drug

CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study

Fineline Cube May 23, 2025

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...

Company Deals

Viz.ai Partners with Sanofi and Regeneron to Deploy AI Solution for COPD

Fineline Cube May 23, 2025

US-based Viz.ai this week announced a multi-year partnership with France-based Sanofi (NASDAQ: SNY) and US-based...

Company Drug

GSK’s Nucala Receives FDA Approval for COPD Treatment

Fineline Cube May 23, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Drug

Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment

Fineline Cube May 23, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the commercial launch of its hypoxia-inducible...

Company Drug

NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment

Fineline Cube May 23, 2025

China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...

Company Drug

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025

Fineline Cube May 23, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...

Posts pagination

1 … 191 192 193 … 701

Recent updates

  • Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes
  • GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
  • Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
  • Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership
  • Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.